Latest Biotechnology News

Page 3 of 115
Radiopharm Theranostics has reached final alignment with the U.S. FDA on a single pivotal Phase 3 trial for RAD101, its brain metastases imaging agent. The approximately 280-patient study is expected to begin dosing in the first half of 2027, moving the program from regulatory planning towards execution.
Ada Torres
Ada Torres
4 Nov 2026
Percheron Therapeutics has lodged a prospectus for up to 280 million options linked to its earlier $2.3 million placement, with the securities carrying a $0.01 exercise price and expiring in April 2028. The filing raises no meaningful cash on issue, but could provide up to $2.8 million if all options are later exercised while adding a potentially dilutive layer to the capital structure.
Victor Sage
Victor Sage
4 Nov 2026
Amgen delivered 8% third-quarter revenue growth and a 19% increase in GAAP diluted EPS, while newer medicines continued to expand. The result came alongside sharp declines in Prolia and XGEVA sales from biosimilar competition and a busy pipeline of late-stage programmes.
Victor Sage
Victor Sage
4 Nov 2026
Vertex has raised its full-year 2026 revenue guidance after third-quarter sales climbed 12%, but the Crinetics acquisition sharply increased costs and debt. The next major test arrives on 30 November, when US regulators are due to rule on povetacicept for IgA nephropathy.
Ada Torres
Ada Torres
3 Nov 2026
Noxopharm has secured a $1.5 million placement and agreed to convert $3.78 million of shareholder notes as it prepares to test SOF-SKN in cutaneous lupus patients. The funding eases an immediate cash constraint, but the package also brings substantial dilution and remains partly subject to shareholder approval.
Ada Torres
Ada Torres
2 Nov 2026
The FDA has granted orphan drug designation to Neuren’s NNZ-2591 for neonatal hypoxic-ischemic encephalopathy, giving the programme potential US exclusivity and regulatory fee relief. The company is completing a juvenile animal safety study before targeting an IND submission in the first half of 2027.
Victor Sage
Victor Sage
2 Nov 2026
Neurizon Therapeutics has secured A$4.3 million through a discounted placement and is seeking another A$2.0 million from eligible shareholders, while redeeming its remaining Obsidian convertible notes. The move removes current note-conversion dilution, but shifts funding risk towards equity holders ahead of a pivotal NUZ-001 trial readout.
Ada Torres
Ada Torres
2 Nov 2026
INOVIQ has secured a validation agreement with Sonic Healthcare USA for its EXO-OC ovarian cancer test, opening a potential route into the US laboratory-developed test market. The commercial opportunity remains conditional: Sonic has not committed to a licence, and validation is expected to run for 12 to 18 months.
Ada Torres
Ada Torres
2 Nov 2026
Percheron Therapeutics has received a US FDA Safe to Proceed letter for Vanderbilt Health to begin an investigator-sponsored trial of HMBD-002 in combination with venetoclax and azacitidine. The early-stage study will target up to 20 patients with relapsed or refractory AML or AML with MDS.
Ada Torres
Ada Torres
2 Nov 2026
Radiopharm Theranostics is preparing to start a pivotal RAD101 brain-metastases imaging trial in early 2027 after a successful FDA meeting. The clinical progress comes with a sharper funding question: the company reported A$7.46 million in cash against A$10.69 million of quarterly operating outflows, before a subsequent A$8 million tax-incentive-backed advance.
Ada Torres
Ada Torres
30 Oct 2026
Syntara has reported statistically significant exploratory results for its Parkinson’s-related drug SNT-4728, while advancing blood-cancer and scar studies. The quarter also brought A$4.7 million in R&D funding, but the liquidation of a former buyer threatens a facility relocation and recovery of about A$0.6 million.
Ada Torres
Ada Torres
30 Oct 2026
Zelira Therapeutics has only A$47,000 in cash after a quarterly operating outflow of A$56,000, while the proposed US$32.98 million HOPE 1 fundraising remains unclosed. The company says the funds are needed for an FDA application and Phase 1 trial, as its ASX quotation suspension continues.
Victor Sage
Victor Sage
30 Oct 2026

Browse the archive

Full archive